A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Germany- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Germany40 clinical trials in Bayreuth, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
GermanyThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical trials focusing on hematologic malignancies and solid tumors, including studies on chronic myeloid leukemia, multiple myeloma, and various types of breast cancer.
Research emphasizes novel drug combinations and treatment strategies to improve patient outcomes.
Extensive research into multiple sclerosis treatments, including evaluations of new therapies and long-term safety studies of established medications.
Studies focus on both relapsing and progressive forms of neurological conditions.
Investigation of various treatment modalities including targeted therapies, immunotherapies, and combination treatments across multiple disease areas.
Focus on developing personalized treatment strategies and improving patient outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.